PCT & Endocrine Recovery

The most prevalent dose-limiting haematological adverse effect of exogenous testosterone and synthetic anabolic-androgenic steroids (particularly Boldenone Undecylenate, Oxymetholone, and high-dose Testosterone esters) is secondary erythrocytosis—an expansion of total red blood cell mass that elevates whole-blood haematocrit (Hct) and haemoglobin (Hb). While a modest rise in oxygen-carrying capacity enhances muscular endurance and work recovery, allowing haematocrit […]

No endocrine variable in male performance pharmacology is more frequently mismanaged than 17-beta-estradiol (E2). For decades, empirical bodybuilding protocols treated estradiol as a purely deleterious hormone responsible only for gynecomastia and subcutaneous water retention, leading athletes to ingest high doses of Aromatase Inhibitors (AIs) prophylactically from day one of a cycle. Contemporary clinical endocrinology has […]

The cessation of exogenous anabolic-androgenic steroids precipitates a biphasic endocrine crisis if left unmanaged. During an active cycle, supraphysiological androgen and estrogen concentrations act upon kisspeptin-neurokinin B-dynorphin (KNDy) neurons in the arcuate nucleus of the hypothalamus and gonadotroph cells in the anterior pituitary, extinguishing the pulsatile release of Gonadotropin-Releasing Hormone (GnRH), Luteinizing Hormone (LH), and […]